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Although the pathogenesis of abdominal aortic
aneurysms (AAAs) is not fully understood, it has
become clear that inflammation plays an important
part in the destruction of the media and its elastin ele-
ments, which is characteristic of the disease.1 In
AAAs, T and B lymphocytes, plasma cells, and
macrophages are all present, but it is the macrophages
in particular that are believed to have a preeminent
role in AAA pathogenesis.2-4 Macrophages secrete
several elastolytic proteases that are members of the
matrix metalloprotease (MMP) family, including
MMP-2, MMP-9, and MMP-12, and these are pro-
duced in increased amounts by macrophages in both
human and experimental aortic aneurysms.4-7
In macrophages, the induction of MMP expres-
sion is dependent in part on the production of
prostaglandin E2 (PGE2). PGE2 is synthesized from
arachidonic acid via a pathway that is rate-limited by
the enzyme cyclooxygenase synthase (cox).8,9 There
are two isoforms of cyclooxygenase, cox1 and cox2.
Cox1 tends to be expressed constitutively, whereas
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cox2 is up-regulated with inflammation. Activation
of macrophages is associated with up-regulation of
cox2 and synthesis of PGE2,10 and human studies
have documented increased PGE2 synthesis associ-
ated with the cox2 isoform in macrophages in
human AAA tissue.11 Based on these observations,
we proposed that blocking cox activity could poten-
tially slow AAA development. Fortuitously, there is a
class of drugs, nonsteroidal anti-inflammatory drugs
(NSAIDs), that inhibits both cox1 and cox2 activity. 
The rat isolated aortic elastase perfusion model
has been proven to be a useful model, and the time
course of aneurysm formation has been well charac-
terized.12,13 There is an initial dilatation of the aorta
associated with the perfusion, and subsequent
aneurysmal degeneration begins on about day 4 and
continues to day 14. In a small preliminary study
with this animal model, indomethacin, an NSAID,
was shown to significantly attenuate aneurysmal
expansion in the initial 7-day postperfusion peri-
od.14 The purpose of this study was to determine if
indomethacin’s effects would be sustained in a
longer time course and to determine the molecular
basis of its effects.
METHODS
Aortic perfusion. Adult male Wistar rats, weigh-
ing 350 to 400 g, were cared for in accordance with
a protocol approved by the Washington University
School of Medicine Animal Studies Committee. Each
rat in the study underwent isolated aortic perfusion as
described by Anidjar et al12 and as used in other stud-
ies from this laboratory.7,14 In brief, rats were anes-
thetized with 6% pentobarbital (0.1 mL/100 g body
weight), and a laparotomy was performed under ster-
ile conditions. The infrarenal abdominal aorta was dis-
sected free of the inferior vena cava, followed by liga-
tion of the inferior mesenteric artery and all lumbar
branches of the aorta caudal to the left renal vein.
Through a separate groin incision, a PE10 polyethyl-
ene catheter (Baxter, McGraw Park, Ill) was intro-
duced into the femoral artery and advanced into the
distal infrarenal aorta. An atraumatic clamp was placed
on the aorta just below the level of the left renal vein,
and a silk ligature encompassing the distal aorta and
the catheter within it was secured just above the aor-
tic bifurcation, thus isolating the catheter tip within
the infrarenal aorta. This isolated segment was per-
fused continuously for 2 hours at 100 mm Hg with 2
mL of volume by means of a syringe pump (Sage
Instruments, Boston, Mass). A total of 195 rats
underwent isolated aortic perfusion. Forty were per-
fused with saline only, and these served as controls.
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The remaining 155 rats underwent perfusion with 25
U/mL porcine pancreatic elastase (type I, Sigma).
After perfusion was completed, the catheter was with-
drawn, the femoral artery was ligated, and flow was
restored in the infrarenal aorta. Preperfusion and
postperfusion aortic diameters were measured in situ
under physiologic conditions by means of a micro-
meter with magnification. The wound was closed, and
each animal was kept in an individual cage. Animals
were killed by lethal overdose of pentobarbital at pre-
determined endpoints of 2, 4, 7, 14, or 28 days.
Before the rats were killed, another laparotomy was
performed and aortic diameters were again measured
in situ under physiologic pressure. Aortas were either
perfusion-fixed in situ for histologic studies with 10%
neutral buffered formalin at 120 mm Hg for 10 min-
utes, excised, and snap frozen for later biochemical
analyses, or excised and used immediately for aortic
whole organ culture.
Drug treatment. After aortic perfusion, the
elastase-perfused animals were divided into two
groups. The rats in the first group received no treat-
ment (n = 82). In the second group, each animal
received daily subcutaneous injections of 1.6 mg/kg
of indomethacin, beginning after aortic perfusion
and continuing until the animal was killed. The ani-
mals were not pretreated with indomethacin before
aortic perfusion. 
Aortic organ cultures. A segment of freshly
harvested aorta was divided into two small pieces,
each approximately 2 mm long. Each segment was
placed into a separate well of six-tissue culture plates.
The specimens were allowed to adhere to the tissue
culture plates, then each well was supplemented with
1.5 mL of culture medium, and the plates were incu-
bated at 37°C in a humidified 5% CO2 atmosphere.
After 72 hours, the conditioned media was collected
and stored at –20°C, until they were used for
enzyme-linked immunosorbent assay (ELISA) or
substrate gel zymography.
Enzyme-linked immunosorbent assay. For
the assay, the pooled culture media for each aorta
was assayed. PGE2 was quantified by means of com-
petitive-binding indirect ELISA, as previously
described.11 Each sample was measured in triplicate.
Standard curves were included in each assay.
Histology. Perfusion-fixed aortas were immersed
in 10% neutral buffered formalin overnight at 4°C,
dehydrated through graded ethanols, and embedded
in paraffin. Specimens were cut in cross section at 5
m m and attached to glass slides. Sections were stained
with Verhoeff-van Gieson for elastin and with hema-
toxylin and eosin for routine histological examination.
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Immunohistochemistry. Paraffin-embedded
sections were also used for immunohistochemistry.
The sections were deparaffinized and rehydrated,
and endogenous peroxidase activity was quenched
by incubation with 0.3% H2O2 at room temperature
for 30 minutes. Sections were then incubated with
appropriate antibodies, anti-PGE2, anti-ED2 anti-
gen (for macrophages), anti-cox2, or anti-MMP-9
antibodies, or with 10% horse serum (control). The
immune complexes were detected by means of
immunoperoxidase staining with a Vectastain Elite
kit (Vector Laboratories, Burlingame, Calif). The
sections were then counterstained in preparation for
histologic analysis.
Substrate gel zymography. Aortic culture media
were normalized to total protein, mixed with nonre-
ducing sodium dodecyl sulfate sample buffer, and
resolved by electrophoresis through 10% polyacryl-
amide gels co-polymerized with 1 mg/mL gelatin
(Sigma, St. Louis, Mo), as previously described.15
The gels were incubated overnight at 37°C in 50
mmol/L Tris-HCl, pH 8.5, containing 5 mmol/L
CaCl2 and 0.2% NaN3, then stained with 0.1%
Coomassie blue R-250 in 40% methanol/10% acetic
acid. Enzymes appeared as clear bands against a dark
background of intact substrate, and the relative mole-
cular weight of each band was estimated by compar-
ing the migration positions of known molecular-
weight standards (Bio-Rad, Hercules, Calif) and a
mixture of authentic MMP-9 and MMP-2 (gift of
Howard Welgus, MD, Washington University School
of Medicine). 
In situ hybridization. Probes for in situ
hybridization were prepared as described by Stahl-
Backdahl et al.16 In brief, a 190 base pair (bp) frag-
ment of the 3’ end of rat cox2 complementary DNA
(cDNA; pMon 23916; Monsanto-Searle, St. Louis,
Mo) and a 280 bp fragment of the 3’ end of rat cox1
cDNA (pMon 23918; Monsanto-Searle, St. Louis,
Mo) were subcloned in pGEM5Z transcription vec-
tors (Promega, Madison, Wis) and then linearized.
The RNA probes were transcribed from the lin-
earized cDNA templates and labeled with digoxi-
genin-11-UTP under conditions recommended by
and with reagents from Boerhringer Mannheim
(Indianapolis, Ind). In situ hybridization was per-
formed as described.16 In brief, 5 m m tissue sections
were treated with proteinase K (Sigma Chemical, St.
Louis, Mo), washed in 0.1% mol/L triethanolamine
buffer containing digoxigenin-labeled antisense or
sense RNA probes, and incubated at 42°C for 18
hours in a humidified chamber. After hybridization,
the slides were washed under stringent conditions,
including treatment with ribonuclease-A. The sec-
tions were treated with alkaline phosphatase-conju-
gated antidigoxigenin antibody and 10% normal
sheep serum, followed by 5-bromo-4-chl-3-indoyl
phosphate and nitroblue tetrazolium as chro-
mogens. After development for 4 to 24 hours in the
dark, the color reaction was stopped with Milli-Q
water, and the slides were stained with nuclear-fast
red for final histologic analysis. 
Statistical analysis. Comparisons among the
aortic diameters for all three groups were made with
analysis of variance. Comparisons between the elas-
tase and the indomethacin groups were also made by
means of a paired, two-tailed, Student t test.
RESULTS
The results of the aortic perfusion are depicted
graphically in Fig 1. Aortic perfusion with saline did
not result in any significant change in aortic diameter
at any of the time points. In contrast, perfusion with
elastase resulted in modest aortic dilation initially. The
average aortic diameter in each group was 1.65 mm
preperfusion. By day 2, both of the elastase groups
showed aortic dilatation, with the aortic diameters of
the elastase-only group being 2.43 ± 0.16 mm, as
compared with 2.47 ± 0.11 mm in the indomethacin
group (P > .05). The curves for aortic expansion
remain essentially the same for both the elastase-only
and the indomethacin groups through day 4 (Fig 1),
when aortic diameters were 2.73 ± 0.19 mm and 2.60
± 0.20 mm (P > .05), respectively. However, by day
7, there was a marked divergence in average aortic
diameters, with rapid aortic expansion in the elastase-
only group (3.87 ± 1.28 mm vs 2.81 ± 0.55 mm; P <
.01). Aortic dilatation continued through day 14,
with average aortic diameters of 5.27 ± 2.37 mm in
the elastase-only group and 3.45 ± 1.11 mm in the
indomethacin group (P = .01). In contrast, there was
no aortic dilatation in the saline-only group. By day
28, no further aortic dilatation took place, and the
final aortic diameters were actually slightly less than at
day 14, with an average aortic diameter of 4.81 ± 1.70
mm in the elastase-only group, as compared with
3.18 ± 1.31 in the indomethacin group (P = .001).
The results of the PGE2 ELISA are depicted in
Fig 2. Whole organ culture was performed on at
least three aortas from each time point. In the con-
trol (saline-only) group, there was little variation in
PGE2 synthesis above baseline. In contrast, the elas-
tase-only group showed a sharp increase in PGE2
synthesis that paralleled aortic expansion, with syn-
thesis markedly increasing on day 4 and peaking on
day 14. Between days 14 and 28, PGE2 synthesis fell
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dramatically, while aortic dilatation stopped. In con-
trast, the rise in PGE2 synthesis in the indomethacin
group was much less than that in the elastase-only
group, as was aortic dilatation.
Substrate gel zymography was performed on
media from the aortic organ cultures. The results
showed that elastase perfusion, but not saline perfu-
sion, was associated with increased MMP-9 activity.
Treatment with indomethacin was associated with a
marked decrease in MMP-9 expression (Fig 3).
By means of the results of the histological exami-
nation, treatment with elastase was demonstrated not
to result in any marked changes in gross elastin archi-
tecture by day 4 (Fig 4). However, after day 4, elastin
destruction became quite pronounced, and by day 7,
most elastic lamellae were severely damaged. By day
14, elastin destruction was nearly complete. The
destruction of elastin coincided with the develop-
ment of an intense inflammatory infiltrate. It also
coincided with aortic dilatation. By day 28, inflam-
mation had subsided, but by this time elastin destruc-
tion was essentially complete (Fig 5). In contrast, the
indomethacin-treated aortas showed much less
elastin destruction. Once again, elastin was intact
through day 4. On day 7, there was evidence of
elastin damage, but it was much less than that seen in
the elastase-only group. Some elastin destruction
continued through day 14, but at both day 14 and
day 28, the aortas from the indomethacin-treated
group maintained some elastin architecture.
PGE2 was demonstrated to be localized to
mononuclear cells within the inflammatory infiltrate
associated with the aortic wall by means of immuno-
staining. Similarly, cox2 was localized to these cells
(Fig 6). PGE2 and cox2 were shown to be present in
the macrophages within the inflammatory infiltrate by
means of co-localization with immunostaining for
macrophages. Little expression of cox1 was noted by
means of immunostaining.
Similar findings to the immunohistochemistry
with specific staining within macrophages for cox2
were demonstrated by means of in situ hybridization
(Fig 7). Very little cox1 expression was noted with in
situ hybridization. Expression within macrophages
was also shown by means of in situ hybridization for
MMP-9.
Fig 1. Graphic representation of aortic diameters in each group with time. Note that the elastase-
only and indomethacin groups are nearly identical until day 4. Also, saline perfusion alone has lit-
tle effect on aortic diameter.
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DISCUSSION 
The effects of a nonspecific cyclooxygenase
inhibitor, indomethacin, on an animal model of aor-
tic aneurysms were investigated. It was shown that
indomethacin markedly diminishes the aortic dilata-
tion associated with elastase perfusion of the aorta,
and its effects persist to 28 days. In untreated ani-
mals who underwent elastase perfusion, marked aor-
tic dilatation occurred, beginning on day 4 and con-
tinuing through day 14, when the average aortic
diameter was 5.27 mm or 319% of the normal aor-
tic diameter. In the indomethacin-treated group, the
average aortic diameter at day 14 was 3.45 mm or
209% of normal aortic diameter. Viewed another
way, indomethacin prevented more than 50% of the
aortic expansion associated with elastase perfusion.
Aortic dilatation correlated with increased PGE2
expression, which began after day 4. This is the
point at which aortic expansion began to occur.
PGE2 synthesis peaked on day 14, which coincided
with peak aneurysmal dilatation and subsequently
subsided to baseline levels by day 28. By this time,
aneurysm expansion had stopped and the inflamma-
tory response had subsided. In animals treated with
saline perfusion only, there was minimal aortic
dilatation and little change in PGE2 synthesis. In the
animals treated with indomethacin, PGE2 synthesis
was markedly decreased, as compared with the elas-
tase-only group; ie, decreased PGE2 synthesis corre-
lated with decreased aneurysmal expansion and
decreased MMP-9 activity. Furthermore, the cox2
isoform appeared to the predominant cyclooxyge-
nase isoform, and its expression was localized to
macrophages.
Although the effects of indomethacin are dramat-
ic, they are not surprising. In human aneurysm dis-
ease, the initiating event is unknown, but medial and
adventitial elastolysis have been implicated as early
critical events.17 AAAs have several salient features,
including the destruction of the elastin elements of
the aortic wall18 and the presence of an inflammato-
ry infiltrate that includes a large number of lympho-
cytes, plasma cells, and macrophages.1 The model
used in these experiments bears many similarities to
the human condition. In the rat model, elastase per-
fusion is the event that starts the process of elastin
degradation; ie, elastolysis is the initiating event. The
time course of aneurysmal development correlates
both to the development of an inflammatory infil-
trate characterized by macrophages, lymphocytes,
and neutrophils13 and the induction of proteases.19
Histologically, this model shows a strong resem-
blance to human AAAs, in that there is destruction
of the structural elements of the aortic wall, particu-
larly elastin. Interestingly, the initial injury with elas-
tase results in only slight dilatation, but the subse-
quent inflammatory response and induction of pro-
teases correlates with aneurysmal degeneration.13,19
This phenomenon was clearly seen in this experi-
ment when aortic diameters remained relatively con-
stant until day 4 postelastase perfusion in both the
treated and untreated animals. Although the cause
of the inflammatory response is unknown, it is like-
ly caused by the elastin injury caused by the elastase.
Elastin degradation products (EDPs) are chemotac-
tic for inflammatory cells in vitro, as are other matrix
degradation products.20 Once elastin is injured, the
EDPs initiate a series of events, ie, the recruitment
of inflammatory cells, which lead to further destruc-
tion of the elastin and other structural elements of
the extracellular matrix of the aorta.
Macrophages appear to be critical in this model. In
fact, AAAs can be induced by the infusion of activated
peritoneal macrophages and plasmin into the aorta.12
Additional evidence implicating the inflammatory
response in this model has been provided by several
other studies. Dobrin documented that cyclosporin
and methylprednisolone, both immunosuppressive
Fig 2. Graphic representation of prostaglandin E2
(PGE2) synthesis with time. Note that saline perfusion
had little effect, whereas in the elastase-only and
indomethacin groups, PGE2 synthesis mirrored aortic
dilatation, with peak synthesis noted on day 14, when aor-
tic dilatation was maximal. By day 28, PGE2 was nearly
back to baseline, and all aortic dilatation had stopped.
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drugs, attenuated aneurysm growth in this model.21
Ricci et al22 demonstrated that treatment with a mon-
oclonal antibody directed against the CD-18 leukocyte
adhesion molecule also attenuated aneurysm growth
and was associated with a marked decrease in the num-
ber of infiltrating macrophages. Most recently, tumor
necrosis factor binding protein, which inhibits the
activity of the proinflammatory cytokine tumor necro-
sis factor, was shown to attenuate aneurysm growth
when measured at the 6-day time point.23
Fig 3. Zymogram of aortic culture medium taken at day 14. On the right is a sample from a saline-
perfused aorta (saline), the next three lanes (elastase) are from the elastase-only group, and the
last three lanes (Indo) are indomethacin-treated aortas. The band at 92 kDa represents matrix
metalloprotease-9 (MMP-9). In the saline group, there is minimal MMP-9 activity. In the elas-
tase-only group, there is significant lytic activity from MMP-9, and in the indomethacin group,
MMP-9 activity is comparable to baseline. This indicates that indomethacin is associated with
decreasing MMP-9 activity.
Fig 4. Aortic tissue that has been stained with Verhoeff-van Gieson stain. The elastin fibers stain
black within the media. Both micrographs were taken of aortas harvested on day 4. On the left is
an elastase-only specimen, and on the right is a specimen from an animal treated with
indomethacin. There is little difference in the architecture of the media between the two aortas at
this point.
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Macrophages have also been implicated in the
pathogenesis of human AAAs. They are known to
play an important role in regulating the turnover of
extracellular matrix in both normal and pathologic
conditions via the secretion of proteases including
MMPs, protease inhibitors, and cytokines. MMPs,
including MMP-2 and MMP-9, which are potent
elastases,24 are elevated in human AAA tissue and are
believed to play a role in the pathogenesis of AAAs.2-4
MMP-9 has been localized to macrophages in
AAAs,2,3,4 as has been urokinase,25,26 which synergis-
tically enhances the ability of macrophages to destroy
extracellular matrix.27 Plasmin, the end product of
urokinase activity and an activator of MMPs, is also
elevated in AAA tissue.28 When viewed together,
these studies strongly suggest that macrophages are
Fig 5. Aortic tissue similar to that shown in Fig 4, except these aortic specimens are from day 28.
On the left is an elastase-only specimen that shows nearly complete loss of elastin fibers within the
media. In the indomethacin-treated aorta, there is an obvious loss of elastin fibers within the media.
In the indomethacin-treated aorta, there is obvious loss of elastin integrity, but much of the elastin
is still intact, indicating that indomethacin helps minimize damage to elastin in this model.
Fig 6. Photomicrograph from an elastase-treated aorta, har-
vested on day 14, that has been immunostained for cox2.
Note the cell-specific hybridization within macrophages in
the inflammatory infiltrate.
Fig 7. Photomicrograph of an in situ hybridization for cox2
on an elastase-only aorta harvested on day 14. Once again,
note the cell-specific hybridization within macrophages in
the inflammatory infiltrate.
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participating in the pathogenesis of AAAs via a syner-
gistic combination of MMPs, urokinase, and plasmin
that degrades the matrix of the aorta.
Indomethacin worked in this experiment, even
though it was given after the initiating event (elastase
perfusion). This indicates that it is not necessary to
prevent the initiating event, but only to intervene in a
timely fashion. This is encouraging for the potential
pharmacologic treatment of AAAs in humans. The
initiating event or events are unknown, but it is a rela-
tively simple matter to identify small AAAs. Currently,
the management of small aneurysms (those smaller
than 4.0 to 4.5 cm) is controversial, because the risk of
rupture in the near future is low; however, the natural
history is that more than 80% of small aneurysms will
eventually require surgical intervention.29 If an 
oral medication that inhibited aneurysm expansion
with a good safety profile were available, it would be
possible to treat small aneurysms pharmacologically.
Unfortunately, NSAIDs, and therefore indomethacin,
have significant adverse effects, such as peptic ulcera-
tion, platelet inhibition, and nephrotoxicity. These
adverse effects are mediated by inhibition of the cox1
isoform of cyclooxygenase, whereas the anti-inflamma-
tory effects are mediated by the cox2 isoform.30,31
Based on the data from this experiment and studies
performed on human AAA organ cultures that docu-
mented that human AAA tissue synthesizes large
quantities of PGE2 and expresses principally the cox2
isoform,11 specific inhibition of cox2 alone would like-
ly result in inhibition of aneurysm expansion. In fact,
specific cox2 inhibitors have been developed. A recent
study performed in rats using NS-398, a selective 
cox2 inhibitor, demonstrated that proinflammatory
prostaglandin synthesis could be effectively blocked
with this drug without the gastric ulcerogenic adverse
effects that were seen with indomethacin in the same
model.32 Cox2 inhibitors are currently in clinical trial
in humans and have minimal adverse effects.33 If cox2
inhibitors prove to be safe, it may be possible to phar-
macologically treat small aneurysms with minimal
morbidity in the near future.
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Dr Timothy Baxter (Omaha, Neb). This is really a
nice piece of work. You’ve linked the cox2 gene and
prostaglandin E2 to the up-regulation of matrix metallo-
protease-9 (MMP-9).
We’ve been interested in the possible role of MMP-2,
and other studies have suggested that MMP-12 may be
involved. Did you use zymography in any case to look at
MMP-12 in this setting? It’s also a macrophage product.
Is it regulated in the same way as MMP-9?
Dr Jeffrey M. Reilly. We have not specifically looked
at MMP-12. The work that Dr Robert Thompson has
been doing at Washington University started a little bit
after this. MMP-12 is something that we’re currently
looking at to see if there’s an effect on its expression by
indomethacin. It is certainly possible that this is one
enzyme that is present. It’s been shown in the work from
Dr Thompson’s laboratory that HME, or human
macrophage elastase, is involved in abdominal aortic
aneurysms in humans.
Dr Baxter. The drug companies have now developed
the specific cox2 inhibitors. I’m sure you’re aware of that.
Has your laboratory started to look at those specific
inhibitors to see how they do in this model?
Dr Reilly. Yes, We have started to look at those, and
according to the preliminary data—we haven’t done all
the biochemical analysis, but certainly on the basis of aor-
tic dilatation—the cox2 inhibitors seem to have the same
effect as indomethacin. We had some trouble in our ani-
mals with indomethacin’s well-known adverse effect of
peptic ulceration and perforation, and we haven’t seen
that in the cox2 inhibitor.
Dr William Pearce (Chicago, Ill). What human dose
is comparable to the indomethacin used in your animals
to obtain that degree of inhibition?
Second, have you given a short pulse of the indo-
methacin at different times or stopped it at different times
to see if this is continuous with your treatment?
Dr Reilly. First, we picked the dose of indomethacin we
use on the milligram-per-kilogram basis; it is the same dose
that’s used to treat humans with rheumatoid arthritis. So
it’s comparable to a human dose; it’s not a suprapharma-
cologic dose.
Regarding the timing of treatment, one of the criticisms
is always how easy it is to treat something if you start before
they have an aneurysm, or whatever it is that one’s looking
at. In this case, it’s important to emphasize that the animals
were not pretreated with indomethacin. It was only given
after the elastase perfusion. We believe that the elastase per-
fusion is the initiating event for the aneurysm formation.
However, we have gone out to the day-4 time point.
We start treating a group of animals not at day 0, but at
day 4, when the two curves are identical. If we start giving
the indomethacin on day 4, the effect is still the same. So,
even in this model, that’s significantly after the initiating
event, and the indomethacin is still effective.
We haven’t gone out to the 7-day point and started
giving indomethacin at 7 days to see if it stops the
aneurysms from expanding at that point.
Dr John Hollett (Rochester, Minn). Those of us who
are interested in pathogenesis of aneurysms know that this
type of work will probably eventually lead to clinical trials,
in which we look at these inhibitors. And one of the
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potential problems with those trials will be that so many of
our patients are already on nonsteroidals; they’re on beta
blockers; they’re on other agents that may already be slow-
ing the growth of aneurysms. And, in fact, as we look in
our practice, we’re impressed now with how many small
aneurysms actually don’t expand much with time.
In your clinical practice, have you looked at any clini-
cal groups of patients, who are either on nonsteroidals or
beta blockers, to see whether the expansion rate is less
than what the literature previously reported? And have
you looked at whether that might be problematic if we’re
thinking about clinical trials?
Dr Reilly. No, we haven’t looked specifically at patients
on nonsteroidals to see if their aneurysm expansion rate is
different. One of the problems is that most of the patients
referred to us, as surgeons, are patients who already have
aneurysms of operable size. I think that the initial studies
that are going to be done with pharmacologic treatment
might best target patients who have relatively large
aneurysms, but who are a prohibitive risk for surgery. That
might be the first place to start.
Identifying small aneurysms requires a big effort, and
I think that trial will be done also, but will be more diffi-
cult to complete.
Dr Howard Greisler (Maywood, Ill). I think this is
very elegant work, and you’ve really made a lot of progress
with this model, but I’m concerned about the human
extrapolation issue. In this model, clearly inflammatory
mediators are important, macrophages are important, and
apparently cox2 isoforms are important in prostaglandin
and MMP production. However, you can suppress things
for a short period very easily in animals, but not very effec-
tively long term.
Do you think, for example, that for clinical use you
would need to suppress the cox2 expression for years and
years? Can that be done, given all the redundancy in the
whole prostaglandin system?
Dr Reilly. I don’t know the answer to that question. I
think you’re right; if we’re going to treat small aneurysms,
it’s going to have to be a long-term proposition.
Regarding the parallels between this model and the
human model, at the biochemical level and the histologic
level, there are a lot of similarities. Human aneurysms, at
least at the stage at which we’ve been studying them,
which is when they come to surgical attention, are charac-
terized by intense inflammation. They have elevated levels
of matrix metalloproteases in the wall. Those same things
are seen in the animal model. Just as in human aneurysms,
the animal models are characterized by destruction of the
elastin elements of the aortic wall. So there are a lot of par-
allels between the two models. However, it’s not perfect;
our aneurysms stop growing at day 14, for example. The
natural history of most human aneurysms is that they con-
tinue to grow. So I don’t know what the difference is
between the models.
However, it will require long-term treatment, and
right now, one of the biggest drawbacks of using a drug
such as indomethacin, one of the approved nonsteroidal
inflammatory drugs, is that they don’t have a great safety
profile, particularly in elderly patients. They’re associated
with a significant incidence of peptic ulceration and
nephrotoxicity, and there are the other recognized bleed-
ing complications, caused by platelet inhibition.
The cox2 inhibitors, at least according to the prelimi-
nary data coming out of the phase 2 clinical trials in
humans, have an outstanding safety profile. I think that it
may be possible, as we learn more about these drugs, to
keep a patient on those drugs for a long period.
